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Abstract Limb girdle muscular dystrophy type 2 (LGMD2)
is a genetically heterogeneous autosomal recessive disorder
caused by mutations in 15 knowngenes. DNA sequencing of
all candidate genes can be expensive and laborious, whereas
a selective sequencing approach often fails to provide a
molecular diagnosis. We aimed to efficiently identify
pathogenic mutations via homozygosity mapping in a
population in which the genetics of LGMD2 has not been
well characterized. Thirteen consanguineous families con-
taining a proband with LGMD2 were recruited from Saudi
Arabia, and for 11 of these families, selected individuals
were genotyped at 10,204 single nucleotide polymorphisms.
Linkage analysis excluded all but one or two known genes in
ten of 11 genotyped families, and haplotype comparisons
between families allowed further reduction in the number of
candidate genes that were screened. Mutations were identi-
fied by DNA sequencing in all 13 families, including five
novel mutations in four genes, by sequencing at most two
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DOI 10.1007/s10048-010-0250-9genes per family. One family was reclassified as having a
different myopathy based on genetic and clinical data after
linkage analysis excluded all known LGMD2 genes. LGMD2
subtypes A and B were notably absent from our sample of
patients, indicating that the distribution of LGMD2 mutations
in Saudi Arabian families may be different than in other
populations.Ourdatademonstratethathomozygositymapping
in consanguineous pedigrees offers a more efficient means of
discovering mutations that cause heterogeneous disorders than
comprehensive sequencing of known candidate genes.
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Introduction
Limb girdle muscular dystrophies are a heterogeneous group
of disorders, with the autosomal recessive type 2 (LGMD2)
caused by mutations in at least 15 genes [1, 2]. Characteriza-
tion of the mutational spectrum of a disease in diverse
populations is necessary to understand its pathogenesis and
epidemiology. The frequencies of different LGMD2 subtypes
and mutations vary considerably by population [1], but to our
knowledge, the genetic profile of LGMD2 in Saudi Arabian
patients has not been previously described. However, it can
be costly and time consuming to screen all known LGMD2
genes (TTN alone has at least 312 exons), and screening only
the seven most commonly mutated genes can fail to yield a
mutation in approximately 30–40% of patients [3, 4].
Homozygosity mapping is an effective technique for
localizing rare recessive mutations, as consanguineous
pedigrees provide disproportionately high power for linkage
analysis relative to the number of individuals genotyped [5].
In addition, high-density microarrays that assay thousands
of single nucleotide polymorphisms (SNPs) allow a more
informative and inexpensive genomewide linkage scan than
conventional microsatellite panels [6]. We hypothesized it
would be cost effective to focus the discovery of pathogenic
LGMD2 mutations by performing SNP-based linkage
analysis on consanguineous families, including those
insufficiently informative to achieve suggestive or signifi-
cant LOD scores. Here, we report the discovery of five
novel mutations in four genes via homozygosity mapping
in 11 Saudi Arabian families, accomplished at a fraction of
the cost required to sequence all 15 LGMD2 genes.
Materials and methods
Thirteen families of Saudi Arabian descent in which
patients appeared to be affected with LGMD2 were
recruited via King Khalid University Hospital and Security
Forces Hospital, Riyadh, Saudi Arabia. Written informed
consent was obtained for all subjects, and de-identified
genomic DNA samples were transferred to Children’s
Hospital Boston, in accordance with the Institutional
Review Boards of the above institutions. The presumed
diagnosis of LGMD2 was made on the basis of clinical
presentation, serum creatine kinase levels, and muscle
biopsy findings (including immunohistochemistry when
available), as summarized in Table 1.
Samples from 11 families were genotyped at 10,204
SNPs using the GeneChip Human Mapping 10K 2.0 Array
(Affymetrix). To minimize costs, we genotyped primarily
affected individuals, with unaffected subjects genotyped as
needed (Fig. 1). Genomewide multipoint parametric linkage
scans were performed using MERLIN v1.1.2 [7]. The
disease allele frequency was set to 0.0001, and we used a
full penetrance, zero phenocopy model. Marker map
positions and Caucasian allele frequencies were provided
by Affymetrix. The error checking and Pedwipe functions
of MERLIN were used to remove unlikely genotypes.
Based on results from families 1186–1191, families 1223–
1229 were screened for mutations in SGCA (also known as
adhalin) and FKRP prior to 10K genotyping; two families
(1224 and 1227) in which mutations were identified were
therefore not genotyped. Amplification of candidate gene
exons and splice junctions by polymerase chain reaction
(PCR) and sequencing of purified products were performed
by standard protocols, and sequence data were analyzed
using Sequencher v4.8 (Gene Codes) and SeqScape v2.5
(Applied Biosystems). Mutations were genotyped in DNA
samples from unrelated control subjects using Custom
TaqMan SNP Genotyping Assays (Applied Biosystems).
Multi-species sequence alignments were performed in
ClustalW [8], and the impact of amino acid substitutions
on protein function was predicted by PolyPhen [9].
Results
The clinical presentations and laboratory results were
generally typical of LGMD2, except in the case of family
1223, in which creatine kinase levels were not elevated and
calf pseudohypertrophy was absent (Table 1). The kindreds
1186–1191 and 1223–1229 were consanguineous and
displayed autosomal recessive inheritance (Fig. 1). Muta-
tions were identified in all 13 families, and for the 11
genotyped families, the mutations were in genes implicated
by homozygosity mapping (Table 2). Five families pro-
duced one or more linkage peaks that together contained a
single known LGMD2 gene, including one family (1225)
with a maximum LOD score of 1.8 in which we genotyped
only two affected siblings. Four families generated linkage
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Neurogenetics (2010) 11:449–455 451peaks containing two known LGMD2 genes, including a
family (1228) with a maximum LOD score of 1.2 in which
only a single affected individual was genotyped. For three
families in which two linked genes resided in different
intervals, the LOD score was appreciably higher for the
peak containing the gene in which a mutation was found. In
family 1191, two linked genes in a single interval, SGCA
and TCAP, were both sequenced and TCAP was negative
for mutations.
Family 1226 showed linkage at four known LGMD2
genes, but families 1226, 1228, and 1229 shared a
haplotype in common across a portion of their linkage
peaks containing SGCB (Online Resource 1), allowing us to
correctly predict that all three families carried the same
ancestral mutation in SGCB and thus avoid sequencing the
other five total candidate genes. Two genotyped families
with the c.941C>T (p.T314M) mutation in FKRP also
shared an identical haplotype across FKRP (data not
shown), again implying that these families inherited their
mutation from a common ancestor. A third, ungenotyped
family carried this novel mutation as well, suggesting that
c.941C>T may be a founder mutation in Saudi Arabia.
In the 11th genotyped family, 1223, preliminary linkage
results from a single affected individual produced intervals
containing CAPN3 and DYSF. The proband was homozy-
gous for a mutation in DYSF, c.6062G>A (p.R2021Q),
previously reported (as p.R2000Q) to be compound hetero-
zygous in conjunction with a nonsense mutation in a family
with Miyoshi myopathy [10]. However, c.6062G>A was
homozygous in a confirmed unaffected sibling in family
Fig. 1 Pedigrees of 13 families
with autosomal recessive
muscular dystrophy or
myopathy. Squares males,
circles females, filled symbols
affected individuals, partially
black-filled symbols obligate
heterozygous carriers, partially
gray-filled symbols possible
heterozygous carriers, open
symbols unaffected individuals.
Double bars represent
consanguineous unions.
Asterisks denote individuals
genotyped for genomewide
linkage analysis
452 Neurogenetics (2010) 11:449–4551223 and was heterozygous in three of 368 unrelated Kuwaiti
control subjects, indicating either that this variant is a benign
polymorphism or is only pathogenic when combined with a
more severe mutation. Genomewide genotyping of additional
family 1223 members excluded both CAPN3 and DYSF by
linkage, but a linked interval on chromosome 1 contained the
gene SEPN1, in which mutations cause several muscle
diseases, including congenital muscular dystrophy (CMD)
and multiminicore disease (MmD) [11, 12]. Though affected
members of family 1223 showed the typical pattern of
weakness for LGMD, careful review of their clinical data
also revealed scoliosis, respiratory difficulty treated by
tracheostomy, and focal areas of myofibrillar disorganization
and Z-band streaming in biopsy tissue, consistent with a
diagnosis of CMD or MmD. We identified two novel
homozygous missense variants in SEPN1 that segregated
with the disease: c.467T>C (p.L156P) and c.1654G>A
(p.E552K). However, the c.1654G>A variant was heterozy-
gous in eight of 374 unrelated Kuwaiti controls, the p.E552
residue was not completely conserved (Online Resource 2),
and the p.E552K substitution was predicted to be less
detrimental by PolyPhen than p.L156P (data not shown).
Together, these data strongly suggest that c.1654G>A is an
uncommon polymorphism and c.467T>C (p.L156P) is the
pathogenic mutation in family 1223.
Finally, mutations in two commonly mutated genes
(SGCA and FKRP) were found in two additional families
that were not subjected to linkage analysis. In total, we
identified eight pathogenic mutations in six genes in 13
families, of which five mutations in four genes were novel,
while three mutations were previously reported [13–15]. The
three novel missense mutations were absent from at least
368 Kuwaiti control DNA samples, and the novel splice site
mutation was absent from 386 Kuwaiti controls and 105
Southeastern European controls. All four novel pathogenic
missense or splice mutations were completely conserved in
all vertebrate species analyzed (Online Resource 2).
Discussion
We conducted, to our knowledge, the first genetic charac-
terization of LGMD in a Saudi Arabian population. Seven
cases of Miyoshi myopathy from Saudi Arabia have been
described clinically, and though mutations were not
identified in these patients [16], mutations in DYSF have
since been shown to cause both Miyoshi myopathy and
LGMD2B [17]. In our study, homozygosity mapping via
linkage analysis was used to efficiently identify five novel
and three known mutations in five commonly mutated
LGMD2 genes (SGCA, SGCB, SGCD, SGCG, and FKRP)
and a congenital myopathy gene (SEPN1). Multiple alter-
natives to linkage analysis are frequently used for homo-
zygosity mapping [2, 18, 19], usually because they are
technically simpler or computationally faster than a linkage
scan, especially with very large pedigrees or exceptionally
Table 2 Results of linkage analysis and mutation screening
Family Samples
genotyped
Linked known
genes
Maximum possible
LOD score
Maximum actual
LOD scores
Gene with
mutation
Mutation Amino acid
substitution
Novel? Controls
genotyped
1186 5 SGCA 4.941 4.940 SGCA c.101G>A p.R34H No NA
1187 4 FKRP 2.533 2.533 FKRP c.941C>T p.T314M Yes 379
1188 4 FKRP, POMT1 3.135 3.132, 2.240 FKRP c.1012G>T p.V338L Yes 368
1189 5 FKRP 4.038 4.038 FKRP c.941C>T p.T314M Yes
a (379 above)
1190 4 SGCD 2.533 2.533 SGCD c.97C>T p.R33X Yes NA
1191 4 SGCA, TCAP 1.579 1.578 SGCA c.584+5G>A NA Yes 491
1223 8 SEPN1 1.829 1.828 SEPN1 c.467T>C p.L156P Yes 375
1224 0 NA NA NA SGCA c.101G>A p.R34H No NA
1225 2 SGCG 1.806 1.804 SGCG c.525del p.F175LfsX20 No NA
1226 1 SGCB, SGCA,
TCAP, DYSF
1.204 1.204, 1.162,
0.607
SGCB c.541_551del p.S181X No NA
1227 0 NA NA NA FKRP c.941C>T p.T314M Yes
a (379 above)
1228 1 SGCB, SGCG 1.204 1.202, 0.662 SGCB c.541_551del p.S181X No NA
1229 3 SGCB, POMT1 2.408 2.408, 1.359 SGCB c.541_551del p.S181X No NA
LOD scores for each family are reported only for genomic intervals containing linked known genes, and are listed in the same order as those
genes. A single interval contained both SGCA and TCAP in families 1191 and 1226. All mutations were homozygous in affected individuals,
heterozygous in obligate carriers, and absent from all genotyped controls. Mutations were detected in DNA; predicted mutations in protein
sequence were inferred
NA not applicable
aAn additional occurrence of a novel mutation reported herein
Neurogenetics (2010) 11:449–455 453dense marker panels [20]. However, for a trait for which
many genes have been previously identified, the probability
that any particular family will contain a mutation in a
known gene is high, so in this scenario, it is likely more
cost effective for pedigrees with known consanguinity to
limit genotyping to only a select few informative individ-
uals on the most inexpensive SNP-based platforms. Our
study confirms that under these conditions, homozygosity
mapping can be readily accomplished by standard para-
metric linkage analysis [21], which has the benefits over
other methods of distinguishing blocks of autozygosity
from blocks of uninformative markers (which are not
uncommon on high density SNP arrays) when parents
and/or unaffected siblings are genotyped, as well as
providing a measure of the statistical significance of linkage
peaks interpretable by conventional standards.
We further highlight the utility of linkage analysis as a
s c r e e n i n gm e t h o de v e ni nf a m i l i e so fm a r g i n a li n f o r m a -
tivity. Nine of 11 genotyped families produced maximum
LOD scores below the threshold of 3.3 for significant
genomewide linkage, and five of those families fell
below the threshold of 1.9 for suggestive linkage [22].
Nevertheless, linkage analysis excluded at least 13 of the
15 known genes in nine of ten families with LGMD2, and
the LOD scores favored a specific gene in four of five
families in which multiple known genes were linked.
Comparison of haplotype data in linkage peaks shared
among families further improved the power of our
analyses by identifying families with evidence of carrying
the same mutation inheritedf r o mac o m m o na n c e s t o r .
Accordingly, a mutation was identified in nine of ten
genotyped LGMD2 families by sequencing a single gene;
we thereby saved considerably on time and sequencing
costs by conducting linkage scans.
Surprisingly, none of the families showed linkage to
CAPN3 or DYSF, though they are the two most commonly
mutated genes among LGMD2 patients in some popula-
tions [3, 4, 23], suggesting that LGMD2 subtypes A and B
may be less common in Saudi Arabia than elsewhere.
Since both CAPN3 and DYSF require at least 30 amplicons
to sequence their exons, the cost of PCR and bidirectional
Sanger sequencing of either one in a single patient exceeds
the cost of processing one 10K SNP array ($280 at
Children’s Hospital Boston), further illustrating the econ-
omy of our approach. Moreover, the exclusion of all 15
known LGMD2 genes in family 1223 and the subsequent
discovery of mutations in the myopathy gene SEPN1
demonstrate the application of linkage analysis to assist in
resolving ambiguous clinical diagnoses, which may help
account for the high failure rate when searching for
mutations by sequencing alone.
Another alternative to comprehensive sequencing is to
attempt molecular diagnosis by protein analysis, as six of
the seven most commonly mutated LGMD2 genes
(CAPN3, DYSF, SGCA, SGCB, SGCD,a n dSGCG) encode
proteins that are absent or severely reduced by immuno-
blot or immunohistochemistry in the corresponding
LGMD2 subtypes [4]. While this strategy depends on the
availability of well-preserved biopsy tissue, it may be
inexpensive and effective in some cases and thus advan-
tageous for non-consanguineous families or sporadic
patients. However, protein-based diagnostic testing can
be time consuming and laborious, require separate opti-
mization of conditions for each test, or lead to ambiguous
findings, as when a single missing sarcoglycan subunit
causes disruption of other subunits. Like Sanger sequenc-
ing, protein assays involve individual testing of each
hypothesis, and the frequency with which a particular test
will succeed in identifying the molecular defect depends
on the LGMD2 subtype distribution in the population. For
infrequently studied populations, the distribution may be
unknown or unusual, and for patients in which protein
tests are unsuccessful, genetic analyses may then be
necessary, possibly negating any initial cost savings.
By contrast, genomewide homozygosity mapping offers
a single, unbiased, simultaneous test of all possible loci,
and in cases where the most obvious candidate genes are
excluded, linkage data can direct attention to novel genes or
genes associated with similar phenotypes. While homozy-
gosity mapping is most effective in families known to be
consanguineous, it can also be applied successfully to
outbred populations when higher density SNP arrays are
used [24]. Homozygosity mapping may therefore provide a
faster and less expensive approach to molecular diagnosis
of genetically heterogeneous traits in many families than
comprehensive screening of candidate genes by traditional
sequencing methods.
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